Introduction, Study Rationale & Design
|
|
- Darcy Fletcher
- 5 years ago
- Views:
Transcription
1 Introduction, Study Rationale & Design John Buse, MD, PhD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Director, NC Translational and Clinical Sciences Institute Executive Associate Dean, Clinical Research University of North Carolina School of Medicine Chapel Hill, NC, USA
2 Disclosures Consultant: PhaseBio Research support: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, GI Dynamics, Intarcia, J&J, Lexicon, Medtronic, Novo Nordisk, Orexigen, Sanofi, Scion NeuroStim, Takeda, Theracos Stocks/shareholder: PhaseBio Other (advisor under contract between employer and the company): Adocia, AstraZeneca, Dance Biopharm, Eli Lilly, Elycylex, F. Hoffman LaRoche, GI Dynamics, Lexicon, Merck, Metavention, Novo Nordisk, Orexigen, Quest, Takeda, vtv Therapeutics
3
4 Diabetes-related complications in the USA, Acute myocardial infarction Adapted from Gregg EW, et al. N Engl J Med 2014;370:
5 CVD is the leading cause of death in people with T2D *Information on diabetes type (i.e., type 1 or 2) was generally not available, though the age of the participants suggests that the large majority with diabetes would have type 2. In high income countries, up to 91% of adults with diabetes have type 2 3 CVD, cardiovascular disease; CI, confidence interval; T2D, type 2 diabetes. 1. Seshasai et al. N Engl J Med 2011;364:829-41; 2. Centers for Disease Control and Prevention National Diabetes Fact Sheet International Diabetes Federation. IDF Diabetes Atlas, 7th edition. Brussels, Belgium: International Diabetes Federation,
6 All Cause Mortality Intensive vs Standard Glucose Lowering CI: confidence interval; HR: hazard ratio. Ray KK et al Lancet 2009;373:
7 Ussher JR, Drucker DJ. Circ Res 2014;114:
8 Steering Committee Academic Members John Buse USA (Chair) Steven P Marso USA (Co-Chair) Richard Bergenstal USA Gilbert Daniels USA Johannes Mann Germany Michael Nauck Germany Steven Nissen USA Stuart Pocock UK Neil Poulter UK William Steinberg USA Bernard Zinman Canada Sponsor (Novo Nordisk) Kirstine Brown-Frandsen Peter Kristensen Mette Stockner Lasse S Ravn ( ) Alan Moses ( ) Marcin Zychma ( )
9 Global Expert Panel S Akalın, Turkey R Arechavaleta, Mexico S Bain, UK M Babkowski, Spain M Benroubi, Greece L Berard, Canada A Comlekci, Turkey L Czupryniak, Poland M Eriksson, Sweden V Fonseca, USA E Franek, Poland J Gross, Brazil K Hafidh, UAE M Haluzik, Czech Republic F Hayes, Ireland Y-Y Huang, Taiwan S Jacob, Germany G Kaddaha, UAE A Khalil, UAE B Kilhovd, Norway M Laakso, Finland L Leiter, Canada N Lalic, Serbia J Linong, China J Luedemann, Germany E Mannucci, Italy M Marre, France L Masmiquel, Spain M Mota, Romania M Omar, South Africa D O Shea, Ireland CY Pan, China J Petrie, UK T Pieber, Austria R Pratley, USA I Raz, Israel R Rea, Brazil G Rutten, The Netherlands I Satman, Turkey M Shestakova, Russia R Simpson, Australia D Smith, Ireland C Tack, The Netherlands L Tarnow, Denmark N Thomas, India L Van Gaal, Belgium F Travert, France J Vidal, Spain M Warren, USA K-H Yoon, Republic of Korea
10 LEADER: Study design CV: cardiovascular; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonist; HbA 1c : glycated hemoglobin; MEN-2: multiple endocrine neoplasia type 2; MTC: medullary thyroid cancer; OAD: oral antidiabetic drug; OD: once daily; T2DM: type 2 diabetes mellitus.
11 Primary and key secondary outcomes CV: cardiovascular; MACE: major adverse cardiovascular event; MI: myocardial infarction.
12 Event adjudication *Requiring hospitalization. ACS: acute coronary syndrome.
13 LEADER standard of care guidelines CV: cardiovascular; CVA: cerebrovascular accident; HbA 1c : glycated hemoglobin; LDL: low-density lipoprotein; MI: myocardial infarction.
14 Additional committee efforts Data monitoring committee Calcitonin monitoring committee Patient retention panel
15 Study population Neil Poulter, F.Med.Sci Professor of Preventive Cardiovascular Medicine Co-Director of International Centre for Circulatory Health and Imperial Clinical Trials Unit Imperial College London London, UK
16 Disclosures Fees for serving on Steering Committees from AstraZeneca and Novo Nordisk, and lecture fees from Novo Nordisk and Takeda Pharmaceuticals
17 LEADER: A Global Trial
18 Study patient disposition FAS: full analysis set.
19 Baseline characteristics (mean ± SD unless stated) *Heart failure includes New York Heart Association class I, II and III. BMI: body mass index; HbA 1c : glycated hemoglobin.
20 Baseline cardiovascular risk profile Data are number of patients (%). CHD: coronary heart disease; CKD: chronic kidney disease; CVD: cardiovascular disease; egfr: estimated glomerular filtration rate; NYHA: New York Heart Association; TIA: transient ischemic attack.
21 Baseline cardiovascular risk profile Data are number of patients (%). CVD: cardiovascular disease.
22 Cardiovascular medication at baseline
23 Antihyperglycemic medication at baseline TZD: thiazolidinediones.
24 Trial follow-up and drug exposure *Excluding pre-scheduled 30 day off-treatment follow-up period. Including off-treatment periods. IQR: interquartile range.
25 UNIVERSITY OF TORONTO Clinical & Metabolic Outcomes Bernard Zinman, CM, MD, FRCPC, FACP Director, Leadership Sinai Centre for Diabetes Sam and Judy Pencer Family Chair in Diabetes Research Senior Scientist, Lunenfeld-Tanenbaum Research Institute Professor of Medicine, University of Toronto Mount Sinai Hospital Toronto, Canada
26 Disclosures Consultations and Honoraria Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi Grant Support Boehringer Ingelheim, Novo Nordisk, Astra Zeneca
27 HbA 1c Data are estimated mean values from randomization to month 48. CI: confidence interval; ETD: estimated treatment difference; HbA 1c : glycated hemoglobin.
28 Antihyperglycemic medication at baseline TZD: thiazolidinediones.
29 Antihyperglycemic medications introduced during trial DPP-4: dipeptidyl peptidase-4; GLP-1RA: glucagon-like peptide-1 receptor agonist; SGLT-2: sodium-glucose co-transporter-2; TZD: thiazolidinedione.
30 Body weight Data are estimated mean values from randomization to last scheduled visit for body weight measurement (month 48). CI: confidence interval; ETD: estimated treatment difference.
31 Cardiovascular medication introduced during trial
32 Blood pressure Data are estimated mean values from randomization to last scheduled visit for blood pressure measurement (month 48). CI: confidence interval; DBP: diastolic blood pressure; ETD: estimated treatment difference; SBP: systolic blood pressure.
33 Heart rate Data are estimated mean values from randomization to last scheduled visit for heart rate measurement (month 48). Bpm: beats per minute; CI: confidence interval; ETD: estimated treatment difference.
34 Cholesterol Data are observed geometric mean values from randomization to last scheduled visit for LDL and HDL cholesterol measurement (month 48). CI: confidence interval; ETD: estimated treatment difference; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
35 Health-related quality of life Patient-reported outcomes EQ-5D index score and VAS score EQ5D Index score Mobility Self-care Usual activities Pain/discomfort Anxiety/depression Worst EQ5D VAS score Assessment of health state by the visual analogue scale Imaginable health state Best
36 Quality of life: EQ5D Full analysis set. Estimated means. Change from baseline to 3-year assessment analysed using a linear mixed model accounting for repeated measures within patients using an unstructured residual covariance matrix. Interaction between visit and respectively treatment, sex, region and antidiabetic therapy at baseline are included as fixed effects and interaction between visit and respectively baseline EQ5D Index/VAS score and age at baseline are included as covariates. CI: confidence interval; EQ5D: EuroQol 5 Dimensions; ETD: estimated treatment difference; VAS: visual analog scale.
37 Cardiovascular Outcomes Steven Marso, MD Medical Director of Interventional Cardiology Professor Internal Medicine University of Texas Southwestern Medical Center Dallas, TX, USA
38 Disclosures Consulting fees from Novo Nordisk and Astra Zeneca, honoraria for physician education from Abbott, and grant support to his institution from Novo Nordisk
39 Primary outcome CV: cardiovascular; MACE: major adverse cardiovascular event; MI: myocardial infarction.
40 Confirmatory statistical analysis CI: confidence interval; CV: cardiovascular; MACE: major adverse cardiovascular event; MI: myocardial infarction.
41 Analyses of MACE and time to first event CV: cardiovascular; MACE: major adverse cardiovascular event; MI: myocardial infarction.
42 Primary outcome CV death, non-fatal myocardial infarction, or non-fatal stroke The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke. The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportional-hazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; CV: cardiovascular; HR: hazard ratio.
43 Primary outcome: Sensitivity analysis Analyzed using Cox proportional hazard regression with treatment as a fixed factor. FAS: full analysis set; PP: per protocol.
44 Time to first event analysis
45 CV death The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportional-hazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; CV: cardiovascular; HR: hazard ratio.
46 Time to non-fatal myocardial infarction The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportional-hazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; HR: hazard ratio.
47 Time to non-fatal stroke The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportional-hazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; HR: hazard ratio.
48 Subgroup analyses of the primary outcome
49 Primary outcome: Subgroup analyses Prespecified Cox proportional-hazard regression analyses were performed for subgroups of patients with respect to the primary outcome (first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). P values signify tests of homogeneity for between-group differences with no adjustment for multiple testing. The percentages of patients with a first primary outcome between the randomization date and the date of last follow-up are shown. Race or ethnic group was self-reported. CI: confidence interval.
50 Primary outcome: Subgroup analyses Prespecified Cox proportional-hazard regression analyses were performed for subgroups of patients with respect to the primary outcome (first occurrence of death from CV causes, nonfatal MI, or nonfatal stroke). P values signify tests of homogeneity for between-group differences with no adjustment for multiple testing. The percentages of patients with a first primary outcome between the randomization date and the date of last follow-up are shown. There were missing data for BMI in 5 patients in the liraglutide group and 4 in the placebo group and for the duration of diabetes in 11 patients in the liraglutide group and 8 in the placebo group.
51 Expanded MACE All-cause death Hospitalization for HF
52 Expanded MACE CV death, non-fatal MI, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or heart failure The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportional-hazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; CV: cardiovascular; HR: hazard ratio; MACE: major adverse cardiovascular event; MI: myocardial infarction.
53 All-cause death The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportionalhazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; HR: hazard ratio.
54 Hospitalization for heart failure The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportionalhazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; HR: hazard ratio.
55 Primary and secondary cardiovascular outcomes* *Hazard ratios and p-values were estimated with the use of a Cox proportional-hazards model with treatment as a covariate. The primary composite outcome in the time-to-event analysis consisted of the first occurrence of death from cardiovascular causes (181 patients in the liraglutide group vs. 227 in the placebo group), non-fatal (including silent) myocardial infarction (275 vs. 304), or non-fatal stroke (152 vs. 163). The p-value is for superiority. The expanded composite outcome included death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina pectoris or heart failure. This analysis was not prespecified. CI: confidence interval; CV: cardiovascular; UAP: unstable angina pectoris.
56 Microvascular Outcomes Johannes Mann, MD Friedrich Alexander University of Erlangen Germany
57 Disclosures Speaker honoraria: Amgen, Astra Zeneca, Braun, Fresenius, Gambro, Medice, Novo Nordisk, Relypsa, Roche Research support: European Union, Canadian Institutes of Health Research, Boehringer, Celgene, Novo Nordisk, Roche, Sandoz Consultant: AbbVie, Astra Zeneca, Celgene, Fresenius, Eli Lilly, Lanthio, Novo Nordisk, Relypsa, Sanifit, Vifor
58 Microvascular event definitions Event type Event definition one or more of the below New onset of persistent macroalbuminuria Microvascular events Renal Eye Persistent doubling of serum creatinine Need for continuous renal replacement therapy Death due to renal disease Need for retinal photocoagulation or treatment with intravitreal agents Vitreous hemorrhage Diabetes-related blindness
59 Adjudication of microvascular endpoints
60 Microvascular event analyses
61 Baseline renal function Full analysis set. Data are means ± standard deviations or number of patients (percentage of either liraglutide-treated or placebo-treated group). Percentage data refer to proportion of patients. egfr: estimated glomerular filtration rate.
62 Time to first microvascular event The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportionalhazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; HR: hazard ratio.
63 Time to first renal event Macroalbuminuria, doubling of serum creatinine, ESRD, renal death The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportionalhazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; ESRD: end-stage renal disease; HR: hazard ratio.
64 Time to first eye event Photocoagulation or treatment with intravitreal agents, vitreous hemorrhage or blindness The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportionalhazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; HR: hazard ratio.
65 Microvascular events %: percentage of group; CI: confidence interval; HR: hazard ratio; N: number of patients; Rate: incidence rate per 100 patient-years of observation.
66 Time to first microvascular endpoints Full analysis set. EAC-confirmed microvascular events including events with onset between date of randomization and date of follow-up. Cox proportional hazard model adjusted for treatment. Development of diabetes-related blindness was not analyzed as an individual component as only one event was observed. *New onset of persistent macroalbuminuria: urine albumin 300 mg/g creatinine. Persistent doubling of serum creatinine level and egfr 45 ml/min/1.73 m 2 per MDRD. %: proportion of patients; CI: confidence interval; EAC: event adjudication committee; N: number of patients.
67 Safety Michael Nauck, MD St. Josef-Hospital (Ruhr University) Bochum, Germany
68 Disclosures Board Member/Advisory Panel: Boehringer Ingelheim, Menarini/Berlin-Chemie, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Novo Nordisk, Takeda Consultant: AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, MetaCure, Versatis, Xoma Employee: St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany Research Support: Bayer Vital, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche, Menarini/Berlin-Chemie, Merck Sharp & Dohme, Novartis, Novo Nordisk (to my institution) Speaker Bureau: AstraZeneca, Menarini/Berlin-Chemie, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Takeda Stock/Shareholder: None Travel support in conjunction with above-mentioned activities
69 Overview of adverse events
70 Adverse events Full analysis set. A serious adverse event was defined as an experience that at any dose resulted in any of the following: death, a life-threatening experience, in-patient hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may jeopardize the patient based upon appropriate medical judgement. A severe adverse event was defined as an adverse event that resulted in considerable interference with the patient s daily activities. N: number of patients.
71 Selected adverse events of special interest Serious adverse events and nonserious medical events of special interest were identified by search in the Medical Dictionary for Regulatory Activities, version 18.0, or by action to trial product: trial product permanently discontinued due to adverse event. P-values were calculated by means of Pearson s chi-square test.
72 AEs leading to permanent treatment discontinuation *Exploratory analysis with no adjustment of p-values for multiplicity. Permanent discontinuation of the treatment regimen was indicated by the investigator in the adverse event form. P-values were calculated by means of Pearson s chi-square test.
73 Hypoglycemia
74 Hypoglycemia Full analysis set. Confirmed hypoglycemia was defined as plasma glucose level of less than 56 mg per deciliter (3.1 mmol per liter) or a severe event. Hypoglycemic episodes on and after randomization date and up to visit 15 (end of treatment) are included (episodes with a missing date are included). %: proportion of subjects; ADA: American Diabetes Association; N: number of subjects; PG: plasma glucose; R: event rate per 100 observation years.
75 Hypoglycemia Confirmed hypoglycemia was defined as plasma glucose level of less than 56 mg per deciliter (3.1 mmol per liter) or a severe event. Severe hypoglycemia was defined as hypoglycemia for which the patient required assistance from a third party. Analyzed using a negative binomial regression model. CI: confidence interval; PG: plasma glucose.
76 Neoplasms
77 Neoplasms Confirmed by adjudication *EAC-confirmed neoplasms with EAC onset date from randomization date to follow-up; includes malignant, pre-malignant, benign and unspecified neoplasms. Neoplasms were adjudicated by the event adjudication committee. This committee interpreted neoplastic growth as clonal disorders that grow in an autonomous manner. The abnormality of clonal disorder may not always have been identified nor could autonomous growth always be determined, but both were considered to be fundamental aspects of neoplastic growth. Cox proportional hazard regression model adjusted for treatment. %: proportion of patients; CI: confidence interval; EAC: Event Adjudication Committee; N: number of patients.
78 Malignant neoplasms by tissue type Confirmed by adjudication Exploratory analysis. CI: confidence interval.
79 Pancreatic cancer
80 Thyroid neoplasms No change in calcitonin P-values were calculated by means of Pearson s chi-square test. %: proportion of patients; N: number of patients.
81 Exocrine pancreas Pancreatitis
82 Pancreatic enzymes Data are observed geometric mean values from randomization to the last scheduled visit for lipase and amylase measurements (month 48).
83 Pancreatitis (confirmed by adjudication) Full analysis set. The occurrence of pancreatitis was adjudicated by the event adjudication committee. P-values were calculated by means of Pearson s chi-square test. %: proportion of patients; N: number of patients.
84 Conclusions John Buse, MD, PhD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Director, NC Translational and Clinical Sciences Institute Executive Associate Dean, Clinical Research University of North Carolina School of Medicine Chapel Hill, NC USA
85 Number needed to treat to prevent one CV: cardiovascular; MACE: major adverse cardiovascular event.
86 Perspective
87 Glucagon-like peptide-1 receptor agonists ELIXA Time to first occurrence of CV death, non-fatal MI, non-fatal stroke or hospitalization for unstable angina LEADER Time to first occurrence of CV death, non-fatal MI or non-fatal stroke CI: confidence interval; CV: cardiovascular; HR: hazard ratio; MI: myocardial infarction. Pfeffer MA et al. N Engl J Med 2015;373:
88 Empagliflozin and Liraglutide EMPA-REG OUTCOME CV death, non-fatal MI, or non-fatal stroke LEADER CV death, non-fatal MI, or non-fatal stroke CI: confidence interval; CV: cardiovascular; HR: hazard ratio; MI: myocardial infarction. Zinman B et al. N Engl J Med 2015;373:
89 Individual components of the primary endpoint EMPA-REG OUTCOME LEADER *95.02% CI. CV: cardiovascular; Empa: empaglifloin; Lira: liraglutide; MACE: major adverse cardiovascular event; MI: myocardial infarction; Pbo: placebo. Zinman B et al. Presented at European Association for the Study of Diabetes 2015, Stockholm, Sweden.
90 LEADER: Summary Population studied High risk of cardiovascular events receiving standard of care 81% with prior CVD or CKD Potentially greater benefit in established CVD and egfr <60 ml/min/1.73 m 2 subgroups Follow-up and retention 96.8% of patients completed the study Vital status known for 99.7% of patients Robust event adjudication by external committee CKD: chronic kidney disease; CVD: cardiovascular disease; egfr: estimated glomerular filtration rate.
91 LEADER: Summary (2) Liraglutide reduced the risk for 3-point MACE by 13% All 3 components of MACE contributed to the risk reduction Liraglutide reduced composite microvascular endpoints Driven by reduced new and persistent macroalbuminuria Liraglutide resulted in reductions in HbA 1c, body weight, and hypoglycemia Liraglutide was generally well tolerated. In line with previous trials, liraglutide was associated with gastrointestinal side effects, increases in pancreatic enzymes and heart rate HbA 1c : glycated hemoglobin; MACE: major adverse cardiovascular event.
92 LEADER: Summary (3) No increase in pancreatitis but an increase in acute gallstone disease No increase in hospitalization for heart failure Liraglutide reduced the risk of all-cause death by 15% Liraglutide reduced the risk of CV death by 22% CV: cardiovascular.
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationLEADER and EMPA-REG. John Buse, MD, PhD. University of North Carolina School of Medicine Chapel Hill, NC, USA. Duality of Interest Declaration
1 LEADER and EMPA-REG John Buse, MD, PhD University of Nth Carolina School of Medicine Chapel Hill, NC, USA Duality of Interest Declaration I rept the following potential duality/dualities of interest
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationabstract n engl j med 375;4 nejm.org July 28,
The new england journal of medicine established in 1812 July 28, 216 vol. 375 no. 4 and Cardiovascular Outcomes in Type 2 Diabetes Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown Frandsen,
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationNEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes
NEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes Moderated by: Bernard Zinman, MD, CM, FRCPC, FACP Lunenfeld-Tanenbaum Research Institute and University of Toronto Mount Sinai Hospital
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationNEWS BRIEFING Diabetes and Cardiovascular Disease. Moderated by: Robert Eckel, MD University of Colorado
NEWS BRIEFING Diabetes and Cardiovascular Disease Moderated by: Robert Eckel, MD University of Colorado 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in any
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationTREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017
TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationKenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationRandomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren 1, Robert P Giugliano 2, Frederick Raal 3, David
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
The new england journal of medicine Original Article and Cardiovascular Outcomes in Patients with Type 2 Diabetes Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz,
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationLiraglutide and Glycaemic Outcomes in the LEADER Trial
Diabetes Ther (2018) 9:2383 2392 https://doi.org/10.1007/s13300-018-0524-z ORIGINAL RESEARCH Liraglutide and Glycaemic Outcomes in the LEADER Trial Bernard Zinman. Michael A. Nauck. Heidrun Bosch-Traberg.
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationCardiovascular Safety of Incretin Based Therapy
Cardiovascular Safety of Incretin Based Therapy John B. Buse, MD, PhD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Executive Associate Dean, Clinical Research University of
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationContent Development Committee
1 Content Development Committee Cardiologists: Family Physicians: Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA, FCCS (Chair) Associate Head, Division of Cardiology, St. Michael s Hospital Professor,
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationModelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford
Oxford Technology Showcase 2016 Big Healthcare Challenges in chronic disease Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford Chronic diseases.. are long-term
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationType 2 diabetes and cardiovascular risk: the role of GLP-1
Type 2 diabetes and cardiovascular risk: the role of GLP-1 Dr Isidora Kitsou-Mylona, PhD Novo Nordisk Regional Medical Advisor Business Area Africa, Gulf & India Disclaimer I am an employee of Novo Nordisk
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationABSTRACT. uncontrolled on basal insulin? OADs;
Diabetes Ther (2017) 8:673 682 DOI 10.1007/s13300-017-0252-9 BRIEF REPORT Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationDiabete mellito e complicanze cardiovascolari: dimensione del problema, bisogni ed evoluzioni terapeutiche
ROADSHOW DIABETOLOGIA DIABETE MELLITO E COMPLICANZE CARDIOVASCOLARI Milano, 5 dicembre 2018 Diabete mellito e complicanze cardiovascolari: dimensione del problema, bisogni ed evoluzioni terapeutiche Stefano
More informationLiraglutide and Renal Outcomes in Type 2 Diabetes
The new england journal of medicine Original Article and Renal Outcomes in Type 2 Diabetes Johannes F.E. Mann, M.D., David D. Ørsted, M.D., Ph.D., Kirstine Brown Frandsen, M.D., Steven P. Marso, M.D.,
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationFaculty. Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY
Faculty Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY 2 Disclosures Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca,
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationFOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?
FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and
More informationLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10
6 Diabetes Care Volume 41, January 2018 PERSPECTIVES IN CARE Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6 10 https://doi.org/10.2337/dc17-1223
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More information